Clinical Trial Update: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating apalutamide with or without stereotactic body radiation therapy in castration-resistant prostate cancer completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)

Snippet

Sponsor: University of California, San Francisco | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-01-21